Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
160
days
Salidroside regulates blood-brain barrier integrity via Lcn2-NLRP3 signaling axis inhibition for high-altitude hypoxic brain injury intervention
Authors
Fuhan Fan; Min Chen; Jierui Yan; Hongyu Jiang; Ya Hou; Yi Zhang; Xianli Meng; Nanjia Cairang; Xiaobo WangShow moreShow less
Affiliations
Chinese Medicine Germplasm Resources Innovation and Effective Uses Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, Sichuan, China; TCM Prevention and Treatment of Metabolic and Chronic Diseases Key Laboratory of Sichuan Province, Institute of High Altitude Multimorbidity/TCM-Integrated High Altitude Medicine Center, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, Sichuan, China; Department of Tibetan Medicine, Xizang University of Tibetan Medicine, Lhasa, 850000, Xizang, China; Innovative Institute of Chinese Medicine and Pharmacy / Institute of Interdisciplinary Studies, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, Sichuan, ChinaShow moreShow less
172
days
Levistilide A alleviates pulmonary fibrosis by blocking the cation channel PIEZO1-centered signaling pathway in fibroblasts
Authors
Qi Han; Ranyun Chen; Yun Yang; Silei Li; Minghang Dong; Xiaotong Cai; Runping Liu; Hong Wang; Guifang Fan; Tiegang Liu; Xiaohong Gu; Xiaojiaoyang LiShow moreShow less
Affiliations
School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, China; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, ChinaShow moreShow less
100
days
Targeting ferritinophagy via NCOA4–FTH1 disruption by sodium tanshinone IIA sulfonate alleviates cardiotoxicity and enhances anti-tumor efficacy
Authors
Ying Liu; Xinzhong Li; Ziru Dai; Min Wang; Shan Gao; Youyou Yan; Zhiwei Liu; Jingxue Ye; Junnan Wang; Guibo SunShow moreShow less
Affiliations
Department of Cardiology, The Second Hospital of Jilin University, 4026Yatai Street, Changchun, Jilin, 130041, PR China; Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development,Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100193, PR China; Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing, China; College of Pharmacy, Harbin University of Commerce, Harbin, ChinaShow moreShow less
209
days
Exploring the potential benefits of combining cannabidiol and beta-caryophyllene for neuropathic and inflammatory pain: A systematic review
Authors
Khalid BenamarShow moreShow less
Affiliations
Institute of Neuroscience and Department of Neuro-behavioral Health, University of Texas Rio Grande Valley, School of Medicine, Biomedical Building, McAllen, TX, 78504, USAShow moreShow less
290
days
Integrating network pharmacology and proteomics to elucidate the mechanism of Allium macrostemon total saponins in alleviating high-altitude acute lung injury
Authors
Keke Liang; Jun Yang; Renjie Wang; Kai Luo; Shuhe Ma; Xia Dou; Yihao Wang; Yue Gao; Xianxie Zhang; Maoxing LiShow moreShow less
Affiliations
College of Pharmacy, Gansu University of Chinese Medicine, Lanzhou, 730000, China; Beijing Institute of Radiation Medicine, Beijing, 100850, China; National Key Laboratory of Kidney Diseases, Beijing, 100850, China; Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China; Drug Safety Technical Inspection Center of Ningxia Hui Autonomous Region, Yinchuan, 750000, ChinaShow moreShow less
57
days
Sodium tanshinone IIA sulfonate attenuates pulmonary vascular remodeling by targeting DYRK1A in pulmonary hypertension
Authors
Zhengwei Dong; Qianqian Lu; Zhifeng Xue; Yong Li; Lan Li; Huan Zhao; Xiaoyao Qin; Zhiang Jiao; Chunmiao Zhan; Hao Deng; Qingyong He; Shuijie Li; Mingjun Zhu; Jian Zhang; Guanwei FanShow moreShow less
Affiliations
The First Affiliated Hospital of Henan University of CM, Heart Center/National Regional (Traditional Chinese Medicine) Cardiovascular Diagnosis and Treatment Center, Zhengzhou, 450000, China; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300381, China; Central Laboratory/Cardiovascular Disease Laboratory for Chinese Medicine, the First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan, 451452, China; Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, 030032, China; Institute of Clinical Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China; Henan University of Chinese Medicine, Zhengzhou, 450046, China; Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science & Technology, Shanghai, 200237, China; Heilongjiang Province Key Laboratory of Research on Molecular Targeted Anti-Tumor Drugs, Harbin, 150080, China; Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, China, Beijing, 100053, ChinaShow moreShow less
FAQ
How long does PHYTOMEDICINE take to review a manuscript?
As of 2026-11-19, CrushSCI has 16 complete review records for PHYTOMEDICINE. The fastest paper went from submission to acceptance in 57 days (Sodium tanshinone IIA sulfonate attenuates pulmonary vascular remodeling by targeting DYRK1A in pulmonary hypertension, received 2026-07-13, accepted 2026-09-08); the slowest took 290 days. The average is 136.8 days and the median is 134.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
